Oncolytic virotherapy needs trials, not access programs

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2595-2597

  Harrington, Kevin J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CGTG 102; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; PELAREOREP; PEXASTIMOGENE DEVACIREPVEC; REOLYSIN; T VEC; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COMPASSIONATE USE; DRUG DEVELOPMENT; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; LIVER CELL CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE SUBPOPULATION; MELANOMA; ONCOLYTIC VIROTHERAPY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; STUDY DESIGN; TREATMENT DURATION; TREATMENT OUTCOME; FEMALE; IMMUNOLOGY; MALE; NEOPLASMS; PROCEDURES; T LYMPHOCYTE;

FEMALE; HUMANS; MALE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; T-LYMPHOCYTES;

EID: 84878041823     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0571     Document Type: Article

References (9)

1. Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, et al. Anti-viral and anti-tumor T-cell immunity in patients treated with GMCSF coding oncolytic adenovirus. Clin Cancer Res 2013;19:2734-44.
2. GM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737-47.
3. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27:5763-71.
4. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008;14:7127-37.
5. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012;18:2080-89.
6. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013;19:329-36.
7. ISRCTN Register. Available from: http://www.controlled-trials.com/ ISRCTN10141600.
8. Docrates Cancer Center. Available from: http://www.docrates.com/images/ stories/laaketutkimukset/Oncos-C1-nettitiedote-Eng-10-Feb2012-final.pdf.
9. Raki M, Sarkioja M, Escutenaire S, Kangasniemi L, Haavisto E, Kanerva A, et al. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. J Gene Med 2011;13: 253-61.